While the unprecedented challenges presented throughout 2020 have undoubtedly changed us all, we would like to take a moment to recognize the outstanding feats our team still managed to accomplish.

1st Quarter

Several Thousand N95 Masks Donated

In response to the COVID-19 pandemic, Frontida has donated several thousand units of personal protection equipment, such as N95 masks and face shields, to local Philadelphia healthcare providers, Temple University Hospital and Saint Joseph's Hospital

2nd Quarter

First IND Filing for FBHRS001

FB-HRS, LLC a joint venture, co-founded by Frontida BioPharm, Inc. and Heart Rhythm Solutions, Inc., announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate its Clinical Trial of FBHRS001, a fixed dose combination (FDC) of two drugs, for the treatment of atrial fibrillation.

3rd Quarter

Highly Potent Manufacturing Suite

Frontida's highly potent compound facility expansion features readily available, hazard-certified production space with the additional inclusion of a large scale Roller Compactor, Milling Room, Bin Blender, Tablet Press, and ingress and egress airlocks with enhanced personnel controls. It is also now available for 2021 quotes.

4th Quarter

Minority-Owned Business Certification

Frontida was granted full certifiable recognition by The Eastern Minority Supplier Development Council, a 501(c)(3) non-profit organization, as a Minority-Owned Business Enterprise. The EMSDC is the only organization capable of providing this specific validation and certification for Pennsylvania, Southern New Jersey, and Delaware businesses throughout the U.S.

2021

Coming Soon: Expansion of Services

Frontida has acquired ownership of AP-accredited and SAMHSA- and CLIAcertified toxicology laboratory research and development department (Cat.One) in the ongoing abuse-deterrent formulation development of CNS products with Drug Scan. These experts have conducted more than 65 Category One in vitro abuse-deterrent studies for both brand and generic ADF developers, and supported the manufacturing of four brand named opioid products.
Come what may, these noteworthy achievements from 2020 have left us with high hopes for the future. However, this remarkable growth phase would have not be possible without your continued support.

So from all of us at Frontida BioPharm, thank you and Happy New Year!